Positron Corporation, a major company providing molecular imaging and nuclear cardiology solutions, is highlighting and article that was discussing the increasing use of cardiac PET. Moreover, Bracco Diagnostics, a company providing contrast agents for cardiac PET, said that the use of its CardioGen-82 cardiac PET myocardial perfusion imaging (MPI) tracer has increased in June 2010 by 46% more than the same period in 2009.
Barcco Diagnostic said that the increased used of the contrast agent was a result to the increased use of cardiac PET as a diagnostic imaging technique, as PET has shown a lot of advances especially in the hardware and software technology. Joseph Oliverio, Chief Technology Officer of Positron, said, "The Bracco release further confirms our market growth prediction. We are seeing an unprecedented request for proposals and look forward to meeting the increasing demand."